Shenzhen Neptunus Interlong Bio-technique Company Limited (8329.HK)
HKD 0.14
(1.41%)
HKD 0.14
(1.41%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 89.68 Million CNY | -3.24% |
| 2022 | 92.69 Million CNY | -12.3% |
| 2021 | 105.69 Million CNY | 950.74% |
| 2020 | 10.05 Million CNY | -76.62% |
| 2019 | 43.02 Million CNY | 378.08% |
| 2018 | 9 Million CNY | -76.92% |
| 2017 | 39 Million CNY | -64.22% |
| 2016 | 109 Million CNY | 0.0% |
| 2015 | 109 Million CNY | -5.22% |
| 2014 | 115 Million CNY | 21.05% |
| 2013 | 95 Million CNY | 10.47% |
| 2012 | 86 Million CNY | 13.16% |
| 2011 | 76 Million CNY | -64.81% |
| 2010 | 216 Million CNY | 58.82% |
| 2009 | 136 Million CNY | -31.31% |
| 2008 | 198 Million CNY | 26.11% |
| 2007 | 157 Million CNY | 20.77% |
| 2006 | 130 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 89.39 Million CNY | 0.0% |
| 2024 Q1 | - CNY | -100.0% |
| 2023 Q2 | 91.93 Million CNY | 0.0% |
| 2023 Q4 | 89.68 Million CNY | 0.0% |
| 2023 Q3 | - CNY | -100.0% |
| 2023 FY | 89.68 Million CNY | -3.24% |
| 2023 Q1 | - CNY | -100.0% |
| 2022 Q2 | 73.26 Million CNY | 0.0% |
| 2022 Q4 | 92.69 Million CNY | 0.0% |
| 2022 FY | 92.69 Million CNY | -12.3% |
| 2022 Q1 | - CNY | -100.0% |
| 2022 Q3 | - CNY | -100.0% |
| 2021 Q2 | 40.75 Million CNY | 0.0% |
| 2021 Q1 | - CNY | -100.0% |
| 2021 FY | 105.69 Million CNY | 950.74% |
| 2021 Q4 | 105.69 Million CNY | 0.0% |
| 2020 Q2 | 39 Million CNY | 0.0% |
| 2020 FY | 10.05 Million CNY | -76.62% |
| 2020 Q1 | - CNY | -100.0% |
| 2020 Q4 | 10.05 Million CNY | 0.0% |
| 2019 Q1 | - CNY | -100.0% |
| 2019 Q2 | 43.76 Million CNY | 0.0% |
| 2019 Q4 | 43.02 Million CNY | 0.0% |
| 2019 FY | 43.02 Million CNY | 378.08% |
| 2018 Q2 | 69 Million CNY | 0.0% |
| 2018 FY | 9 Million CNY | -76.92% |
| 2018 Q4 | 9 Million CNY | 0.0% |
| 2018 Q1 | - CNY | -100.0% |
| 2017 Q2 | 109 Million CNY | 0.0% |
| 2017 Q1 | - CNY | -100.0% |
| 2017 FY | 39 Million CNY | -64.22% |
| 2017 Q4 | 39 Million CNY | 0.0% |
| 2016 Q4 | 109 Million CNY | 0.0% |
| 2016 Q1 | - CNY | -100.0% |
| 2016 FY | 109 Million CNY | 0.0% |
| 2016 Q2 | 109 Million CNY | 0.0% |
| 2015 Q2 | 109 Million CNY | 0.0% |
| 2015 Q4 | 109 Million CNY | 0.0% |
| 2015 Q1 | - CNY | -100.0% |
| 2015 FY | 109 Million CNY | -5.22% |
| 2014 FY | 115 Million CNY | 21.05% |
| 2014 Q2 | 124 Million CNY | 0.0% |
| 2014 Q4 | 115 Million CNY | 0.0% |
| 2014 Q1 | - CNY | -100.0% |
| 2013 Q2 | 95 Million CNY | 0.0% |
| 2013 FY | 95 Million CNY | 10.47% |
| 2013 Q4 | 95 Million CNY | 0.0% |
| 2013 Q1 | - CNY | -100.0% |
| 2012 FY | 86 Million CNY | 13.16% |
| 2012 Q4 | 86 Million CNY | 0.0% |
| 2012 Q2 | 120 Million CNY | 0.0% |
| 2011 Q2 | 82 Million CNY | 0.0% |
| 2011 Q4 | 76 Million CNY | 0.0% |
| 2011 FY | 76 Million CNY | -64.81% |
| 2010 Q2 | 174 Million CNY | 0.0% |
| 2010 FY | 216 Million CNY | 58.82% |
| 2010 Q4 | 216 Million CNY | 0.0% |
| 2009 Q4 | 136 Million CNY | 0.0% |
| 2009 FY | 136 Million CNY | -31.31% |
| 2008 FY | 198 Million CNY | 26.11% |
| 2007 FY | 157 Million CNY | 20.77% |
| 2006 FY | 130 Million CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 6.8 Million HKD | -1216.975% |
| Grand Pharmaceutical Group Limited | 3.4 Billion HKD | 97.365% |
| Extrawell Pharmaceutical Holdings Limited | 120.41 Million HKD | 25.516% |
| Wai Yuen Tong Medicine Holdings Limited | 460.94 Million HKD | 80.543% |
| Qianhai Health Holdings Limited | 487 Thousand HKD | -18316.016% |
| Lee's Pharmaceutical Holdings Limited | 204.14 Million HKD | 56.066% |
| Essex Bio-Technology Limited | 294.02 Million HKD | 69.497% |
| Tongfang Kontafarma Holdings Limited | 333.82 Million HKD | 73.134% |
| PuraPharm Corporation Limited | 424.77 Million HKD | 78.886% |
| SSY Group Limited | 3.37 Billion HKD | 97.342% |
| JBM (Healthcare) Limited | 133.4 Million HKD | 32.773% |
| Jacobson Pharma Corporation Limited | 749.37 Million HKD | 88.032% |
| China Resources Pharmaceutical Group Limited | 85.84 Billion HKD | 99.896% |